Cell Cycle and DDR-Targeted Therapies for Potentiating PD-L1 Blockade: From Molecular Mechanisms to Clinical Translation
SN Comprehensive Clinical Medicine · 22.10.2026 · 8 (1)
DOI: 10.1007/s42399-026-02789-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 22.10.2026. Verfasst von Mano Chitra Karthikeyan und 4 weiteren Autor:innen. Die Arbeit nennt 194 Literaturangaben.
Abstract (Originalsprache)
The intersection of cell cycle (CC)/ DNA damage response (DDR) and immune regulation in cancer represents a promising therapeutic frontier. Targeting proteins that drive CC/DDR not only halts tumor proliferation but also remodels the tumor immune micro environment (TIME) by altering PD-L1 dynamics, enhancing Ag presentation, and inducing chemokines that recruit effector T cells. These effects collectively convert immunologically “cold” tumors into “hot” ones, increasing susceptibility to immune checkpoint blockade (ICB). Importantly, CC/DDR inhibition may transiently elevate PD-L1, potentially enhancing sensitivity to PD-L1 checkpoint blockade in selected contexts. With Fc-competent anti-PD-L1 antibodies, such PD-L1 upregulation may provide greater target availability for Fc-dependent effector functions, including ADCC, depending on antibody properties and cellular context. Thus, treatment scheduling, cellular distribution of PD-L1, and the specific antibody used may influence therapeutic responses. Current biomarkers remain limited by cancer’s biological complexity, tumor heterogeneity, and analytical variability, highlighting the need to identify and validate potential biomarker for predicting PD-L1 therapy response. This review emphasizes the importance of patient stratification and therapeutic optimization in CC/DDR–immunotherapy combinations. Preclinical studies provide evidence of enhanced antitumor activity for selected CC/DDR–PD-L1 combinations, whereas clinical evidence remains heterogeneous and predominantly early-phase. Integrating such regimens with biomarker-based patient stratification, considering CC indices, DDR defects, and tumor infiltrating lymphocytes (TILs) density, could refine therapeutic precision, thereby offering durable avenues for overcoming resistance to monotherapy. Graphical Abstract Tumor cell-cycle dysregulation contributes to immune evasion and may influence responses to PD-L1 therapy, highlighting cell-cycle status as a potential hypothesis-generating biomarker. The ongoing clinical trials that identify the patient subsets of BRCA-mutated, HRR-deficient, and immunologically “cold” tumors that are most likely to benefit from cell cycle/ DDR–immunotherapy combinations. Cell cycle/DDR arrest induced by cell cycle/DDR inhibitors modulates PD-L1 expression as a stress-adaptive response mediated by immune signaling (cGAS-STING/TBK1/IRF3/NF- κB/IFN/JAK-STAT). Contextual IFN exposure alters PD-L1 regulation, underscoring the need to monitor IFN–PD-L1 interactions as part of treatment strategies. The findings highlight the importance of optimizing the timing and duration of cell-cycle and DDR inhibition to balance immune activation and immune suppression and maximize the therapeutic potential of PD-L1 blockade.
Zitieren
APA
Karthikeyan, M. C., Viswanathan, Y., Dinakaran, P., Manivannan, S., & Arockiam, A. J. V. (2026). Cell Cycle and DDR-Targeted Therapies for Potentiating PD-L1 Blockade: From Molecular Mechanisms to Clinical Translation. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02789-8
Vancouver
Karthikeyan MC, Viswanathan Y, Dinakaran P, Manivannan S, Arockiam AJV. Cell Cycle and DDR-Targeted Therapies for Potentiating PD-L1 Blockade: From Molecular Mechanisms to Clinical Translation. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02789-8
BibTeX
@article{Karthikeyan2026,
author = {Karthikeyan, Mano Chitra and Viswanathan, Yuvasri and Dinakaran, Pavithraa and Manivannan, Selvabharathi and Arockiam, Antony Joseph Velanganni},
title = {Cell Cycle and DDR-Targeted Therapies for Potentiating PD-L1 Blockade: From Molecular Mechanisms to Clinical Translation},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02789-8}
}
EUVIMED